139 Main Street, Suite 500
30 articles about ElevateBio
With the complete acquisition of Life Edit, ElevateBio will be able to integrate that company’s genome editing capabilities with its cell and gene therapies.
Boston Children’s Hospital and ElevateBio announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.
ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion
Dr. Roberts brings three decades of expertise to further expand ElevateBio's immunotherapy leadership across its protein, viral, and cell engineering technology platforms
ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering
Award recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, to reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery
3/17/2021Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week.
ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing
- Proceeds to support the acceleration and scaling of ElevateBio’s end-to-end cell and gene therapy technology platform offering - Series C financing led by Matrix Capital Management, joined by additional new investors SoftBank Vision Fund 2 and Fidelity Management & Research Company alongside ElevateBio’s existing investors
Several biotech companies have announced closings of million-dollar financing rounds Monday, with Cambridge, Mass.-based cell and gene therapy company ElevateBio leading the pack. ElevateBio announced it raised $525 million in a Series C financing round, which the company says should help expand ...
ElevateBio to Present at the 39 th Annual J.P. Morgan Healthcare Conference
ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting
Adoptive immunotherapy under investigation for children and adults with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation